TIM
KPTI icon

Tortoise Investment Management’s Karyopharm Therapeutics KPTI Stock Holding History

Tortoise Investment Management’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-147
Closed -$23K – 624
2021
Q2 		$23K Hold
147
– – ﹤0.01% 364
2021
Q1 		$23K Buy
147
+97
+194% +$20.4K 0.01% 344
2020
Q4 		$12K Buy
+50
New +$11.6K ﹤0.01% 396

Other funds holding KPTI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
DMPV
Delphi Management Partners VIII San Mateo, California $138M AUM 56.74% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
LOAMS
Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Tortoise Investment Management's KPTI Position: Q3 2021 in Review

Tortoise Investment Management sold out of Karyopharm Therapeutics (KPTI) in Q3 2021, closing a stake of 147 shares — an estimated $23K sold.

Tortoise Investment Management first reported a position in KPTI in Q4 2020 and held it in 3 quarters. The position peaked at $23K in Q2 2021. 134 funds tracked by Wall St. Rank hold KPTI as of Q3 2021.

  • Tortoise Investment Management reported no remaining Karyopharm Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Tortoise Investment Management sold 147 Karyopharm Therapeutics shares in Q3 2021, an estimated $23K.
  • Tortoise Investment Management first reported a position in Karyopharm Therapeutics in Q4 2020 and held it in 3 quarters.
  • Tortoise Investment Management's Karyopharm Therapeutics position peaked at $23K in Q2 2021.
  • 134 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q3 2021.

Based on Tortoise Investment Management's 13F filing for Q3 2021, filed 4 Nov 2021.